Recommendations Developed for Cost-Effectiveness Analyses

This article originally appeared here.
Share this content:
Recommendations Developed for Cost-Effectiveness Analyses
Recommendations Developed for Cost-Effectiveness Analyses

THURSDAY, Sept. 15, 2016 (HealthDay News) -- A new set of recommendations has been developed for conduct and reporting of cost-effectiveness analyses, according to a report published in the Sept. 13 issue of the Journal of the American Medical Association.

Gillian D. Sanders, Ph.D., from the Duke Clinical Research Institute in Durham, N.C., and colleagues reviewed the state of the field and developed recommendations to improve the quality of cost-effectiveness analyses. Members of the Second Panel on Cost-Effectiveness in Health and Medicine developed recommendations by consensus over 3.5 years. The recommendations were reviewed by external reviewers and via a public posting process.

The authors recommended the concept of a "reference case" and a set of standard methodological practices that all cost-effectiveness analyses should follow in order to improve quality and comparability. Two reference case analyses should be reported in all cost-effectiveness analyses: one based on a health care sector perspective and one based on a societal perspective. The panel also recommended use of an "impact inventory," which is a structured table that includes consequences intended to clarify the scope and boundaries of the two reference case analyses.

"Major changes include the recommendation to perform analyses from two reference case perspectives and to provide an impact inventory to clarify included consequences," the authors write.

Several authors disclosed financial ties to the pharmaceutical industry.

Abstract
Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

FDA Approves Keytruda for All Cancers With Genetic Biomarker

FDA Approves Keytruda for All Cancers With Genetic ...

First medication sanctioned for any cancer, regardless of origin

Regular Chocolate Consumption May Lower Risk of A-Fib

Regular Chocolate Consumption May Lower Risk of A-Fib

13-year study finds lower odds for atrial fibrillation in people eating moderate amounts

Doctors Urged to Check Patient Drug History Before Opioid Rx

Doctors Urged to Check Patient Drug History Before ...

Opioid abuse down when physicians are legally obligated to check patient's drug history

is free, fast, and customized just for you!

Already a member?

Sign In Now »